PRTA — PROTHENA CORP PUBLIC LTD CO
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1559053 ·
Last close
$8.26
Market Cap
$424.15M
52W High
$11.80
52W Low
$7.70
ADV30
497,297
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 620,000 | — | -18,401,000 | -16,509,000 | 283,520,000 | 271,368,000 | 14,683,000 |
| Jun 2026 | 1,010,000 | — | -18,687,000 | -18,583,000 | 302,579,000 | 288,193,000 | 15,688,000 |
| Mar 2026 | 51,084,000 | — | 25,791,000 | 32,721,000 | 349,894,000 | 329,462,000 | 37,278,000 |
| Dec 2025 | 21,000 | — | -27,211,000 | -21,589,000 | 326,804,000 | 307,531,000 | 46,330,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-60,049,000
Investing CF
$-662,000
Financing CF
$-22,531,000
CapEx
$-138,000
Dividends Paid
—
Buybacks
$-22,531,000
EPS Diluted TTM
$-0.84
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,332,295,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-59,868,000
Pretax Income TTM
$-44,350,000
Interest Exp TTM
—
Analysts
5
Yahoo Snapshot (yfinance, live)
Total Revenue
$52,735,000
EBITDA
$-37,700,000
Free Cash Flow
$-19,837,500
Enterprise Value
$144,145,872
Total Cash
$271,368,000
Total Debt
$6,256,000
Shares Out
51,349,796
Trailing EPS
$-0.45
Book Value
$5.24
ROE
-8.5%
ROA
-7.6%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 9,684,000 | -184,560,000 | -244,092,000 | 326,804,000 | 46,330,000 | 280,474,000 | -163,580,000 |
| Dec 2024 | 135,157,000 | -154,561,000 | -122,310,000 | 547,108,000 | 60,182,000 | 486,926,000 | -150,050,000 |
| Dec 2023 | 91,370,000 | -191,036,000 | -147,028,000 | 696,382,000 | 135,017,000 | 561,365,000 | -133,906,000 |
| Dec 2022 | 53,905,000 | -131,557,000 | -116,949,000 | 758,035,000 | 135,993,000 | 622,042,000 | -108,821,000 |
TTM Snapshot
Revenues TTM
$54,530,000
NetIncome TTM
$-43,992,000
OpCashFlow TTM
—
Assets (Latest)
$302,579,000
Forward EPS
$-1.31
Max Pain — expiry 2026-12-18
max pain strike: $9.00 · spot: $8.35 · call oi: 3,780 · put oi: 2,200
Expected Move to 2026-12-18:
±$1.76
(21.08%) —
implied range
$6.59 –
$10.11
· ATM straddle on $8.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CTMX | CytomX Therapeutics, Inc. | $422.93M | $1.94 | — |
| OVID | Ovid Therapeutics Inc. | $418.98M | $2.22 | — |
| OCS | Oculis Holding AG | $417.01M | $7.51 | — |
| AVTX | Avalo Therapeutics, Inc. | $412.28M | $7.13 | — |
| EPRX | EUPRAXIA PHARMACEUTICALS INC. | $437.41M | $6.62 | — |
News headlines (Yahoo Finance, 1h cache)
Insider Buying Signals: 3 Healthcare Stocks to Watch
2026-11-11 15:35 · Yahoo
Wall Street Analysts See a 120.16% Upside in Prothena (PRTA): Can the Stock Really Move This High?
2026-11-10 13:55 · Yahoo
Prothena (PRTA) Reports Q3 Loss, Misses Revenue Estimates
2026-11-06 00:00 · Yahoo
Prothena: Q3 Earnings Snapshot
2026-11-05 22:32 · Yahoo
Prothena Reports Third Quarter 2026 Financial Results and Business Highlights
2026-11-05 21:05 · Yahoo
Prothena to Report Third Quarter 2026 Financial Results on November 5
2026-10-29 20:05 · Yahoo
Prothena's Partnership Strategy: Growth Driver or Limitation?
2026-10-20 15:34 · Yahoo
CRMD vs. PRTA: Which Stock Should Value Investors Buy Now?
2026-10-08 14:40 · Yahoo
Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-09 20:05 · Yahoo
Prothena (PRTA) Reports Q2 Loss, Misses Revenue Estimates
2026-08-06 23:10 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.